Recall that at the end of June, Saransk factory “Biochemist” has launched a cure COVID-19. The Ministry of health of the Russian Federation approved a drug developed here, based on the tools invented in his time in Japan for the treatment of Ebola. Recently, foreign media reported that the Institute of public health Fujita on the results of Japanese clinical trials of the drug failed to confirm its effectiveness. However, according to experts, the Russian medicine is not equivalent to the means produced in the Country of the rising sun.
– this molecule has been carefully refined, – said the press service of the company “Promomed”. – Carried out all analytical studies, developed the technology to calculate dosages, courses, determined by the purity of the substances. The drug showed high activity against RNA viruses, including coronavirus and COVID-19. In the end, all technological solutions are our own.
In the course of large-scale clinical studies produced in Saransk the drug demonstrated high efficiency – more than 90 percent. Already in the first day, 70 percent of patients with coronavirus infection was felt a radical change of state that in the next few days was confirmed by tests. With 80 percent of patients recovered on monotherapy, without concomitant medications. Not registered any case of transfer of disease to a more serious phase.
it Should be noted that a global study funds was carried out in Russia three more companies – and they all came to similar results.
today the drug is enrolled in a Russian clinic and used in the treatment of coronavirus infection.
every day We are monitoring the situation and receive information about the positive effect of the application, – have told in a press-service of the company. – For all health indicators in the majority of patients viral load decreases in the first days. The drug helps to direct, light to medium stage is not moving in heavy. We are ready to cooperate with colleagues from Japan and other countries for further study funds, and provide their data to the international protocols. The management of the company is interested in participating in research programmes with who and other international medical organizations.
Saransk manufacturers are willing to produce up to one million packages of the drug in a month this will fully cover the demand of Russian hospitals.
the Drug is available only in hospitals, under the supervision of doctors. In the long term, the drug can be exported.
